Evidence map›Paper›PMID 33497376›Full record

ArticlePLoS neglected tropical diseases2021

Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina.

María F García-Bustos, Gabriela González-Prieto, Alberto E Paniz-Mondolfi, Cecilia Parodi, Josefina Beckar, Sibila Monroig, Federico Ramos, María C Mora, Lourdes A Delgado-Noguera, Yoshihisa Hashiguchi and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Development of a Fluorescent Assay to Search New Drugs Using Stable tdTomato-Frontiers in cellular and infection microbiology · 2021
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

María F García-BustosInstituto de Patología Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Salta, Argentina.ORCID 0000-0002-7657-8250
Gabriela González-PrietoFacultad de Ciencias de la Salud, Universidad Nacional de Salta, Salta, Argentina.ORCID 0000-0003-1474-4142
Alberto E Paniz-MondolfiInstituto de Investigaciones Biomédicas IDB, Departamento de Enfermedades Infecciosas y Medicina Tropical, Laboratorio de Patología de Enfermedades Infecciosas, Clínica IDB Cabudare, Cabudare, Venezuela.
Cecilia ParodiInstituto de Patología Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Salta, Argentina.ORCID 0000-0001-5589-1443
Josefina BeckarServicio de Otorrinolaringología, Hospital San Bernardo, Salta, Argentina.ORCID 0000-0003-4746-9706
Sibila MonroigServicio de Otorrinolaringología, Hospital Papa Francisco, Salta, Argentina.
Federico RamosInstituto de Patología Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Salta, Argentina.ORCID 0000-0003-1173-5398
María C MoraInstituto de Patología Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Salta, Argentina.
Lourdes A Delgado-NogueraLeishmania Collaborative Network, Emerging Pathogens Division, The Venezuelan Science Incubator, Cabudare, Venezuela.ORCID 0000-0003-0910-5434
Yoshihisa HashiguchiDepartment of Parasitology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Daniela JaimeServicio de Dermatología, Hospital Joaquín Castellanos, Güemes, Salta, Argentina.
Sonia MorenoServicio de Dermatología, Hospital Señor del Milagro, Salta, Argentina.
Luisa Ruiz-MoralesServicio de Dermatología, Hospital San Bernardo, Salta, Argentina.
César G LemirServicio de Infectología, Hospital San Bernardo, Salta, Argentina.
Alejandra BarrioFacultad de Ciencias de la Salud, Universidad Nacional de Salta, Salta, Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARNational University of Salta · ARKōchi University · JPUniversidad Centroccidental Lisandro Alvarado · VE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo date, there is no specific literature available on the determinants for therapeutic failure (TF) with meglumine antimoniate (MA) in Northwestern-Argentina. This study aimed to identify epidemiological, clinical, and treatment-related factors that could be involved in TF. METHODOLOGY/PRINCIPAL

findingsWe performed a case-control study. Cases were represented by patients who showed TF after administration of the first course of MA treatment, whereas, controls were determined as patients who evolved towards healing after the first MA cycle received. Crude Odds Ratios and their corresponding 90% confidence intervals (CI) were calculated, and risk factors were then tested by multivariate analysis using logistic binary regression. Three hundred and eighty-four patients with a presumptive diagnosis of ACL were recruited, and 153 with a positive diagnosis were selected. We included in the study 71 patients, who underwent specific treatment with MA, presented complete data on response to treatment, and had a minimum post-treatment follow-up of 6 months in cutaneous leishmaniasis, and 12 months in mucosal leishmaniasis. Of these, 34 (47.9%) presented TF. In the initial analysis, TF was significantly associated with the geographical area of disease acquisition (p = 0.036), the presence of mucosal lesions (p = 0.042), the presence of concomitant skin and mucosal lesions (p = 0.002), and lesion age ≥ 6 months (p = 0.018). Risk factors influencing TF in the final multivariate model included the geographical area where the disease was acquired (adjusted Odd Ratio 8.062; 95% CI 1.914-33.959; p = 0.004), and lesion age ≥ 6 months (adjusted Odd Ratio 10.037; 95% CI 1.383-72.843; p = 0.023). CONCLUSIONS/SIGNIFICANCE: The results of the present study suggest the existence of some risk factors linked to TF in Northwestern-Argentina, which deserve further investigation. Herein we recorded a high percentage of TF and we described clinical and epidemiological characteristics associated with TF that could be taken into account improving the clinical management of patients.

Indexed as

AdultAntiprotozoal AgentsCase-Control StudiesFemaleHumansLeishmaniasis, CutaneousLogistic ModelsMaleMeglumine AntimoniateMiddle AgedRisk FactorsTreatment FailureAntiprotozoal AgentsMeglumine Antimoniate

Identifiers

PMID33497376
PMCPMC7864468
OpenAlexW3124321054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.